CDMO Momentum in Focus as Q2 FY27 Earnings Loom
Morepen Labs reports Q2 FY27 results on Oct 27. After a breakout Q1 with 34% revenue growth and 394% PAT surge on CDMO ramp, the Street watches for sustained execution on the ₹825 cr mandate and margin sustainability.
The Setup
What matters in Q2: whether Morepen sustains the CDMO revenue and margin trajectory that powered Q1's earnings surprise. After 34% YoY revenue growth and a 394% PAT surge in Q1 FY27 (ending June 30, 2026), fueled by ₹825 Cr CDMO mandate ramp into commercialization, the bar is momentum confirmation. The Street watches three things: (1) incremental CDMO dispatch cadence (expect another ₹225 Cr in supply shipments), (2) whether EBITDA margin holds near 15% despite operating leverage or softens, and (3) whether traditional pharma business offsets any CDMO slowness.
~₹850–₹900 Cr
Implies 50% YoY growth; anchored to Q1's ₹575 Cr baseline + expected ~₹225 Cr incremental CDMO supplies
~15–16%
Q1 FY27 delivered 15.25%; margin hold depends on traditional biz mix + CDMO mix
TBD on tax + finance costs
Q1 saw 394% YoY surge; watch for normalization vs. one-off items
Strong vs. weak Q2: A strong print would show CDMO revenue hitting or exceeding the ₹225 Cr run-rate expectation, EBITDA margin sustained ≥15%, and traditional pharma holding flat or growing low-single-digits. A weak print would see CDMO shipments slip below plan (supply constraint or customer delays), margins compress below 14%, or traditional revenue declining >5% YoY.
On Track?
Morepen is tracking its internal run-rate well. Q1 FY27 marked the ₹825 Cr CDMO mandate's entry into full commercialization, with ₹58 Cr in dispatches in a single quarter. The company has not issued formal Q2 guidance, but management commentary in the Q1 earnings call signaled additional supplies of ~₹225 Cr expected in Q2 under the same mandate. The September 2026 announcement of Phase 1 capacity expansion completion ahead of schedule supports the narrative of execution capability. No full-year guidance to verify yet, but the quarterly trajectory (if sustained at 50% YoY growth) would imply FY27 revenue materially ahead of FY26's implied run-rate.
What the Street Says
Since Last Quarter
1 · CDMO Ramp Confirmed (Aug–Sep 2026)
Q1 FY27 saw ₹58 Cr in CDMO dispatches; capacity Phase 1 expansion completed ahead of schedule (Sep 7, 2026), increasing installed reactor capacity for API and CDMO. Signals strong operational execution for the ₹825 Cr mandate ramp.
2 · US Regulatory Milestone (Sep 28, 2026)
Morepen submitted its first US ANDA for Sitagliptin Tablets (25/50/100 mg) to the FDA. Marks entry into USFDA-regulated segment and adds growth vector beyond domestic markets and CDMO.
3 · Legal Win: GST Refund (Oct 14, 2026)
Morepen Labs won a High Court (Himachal Pradesh) judgment quashing a GST Show Cause Notice. Routine regulatory resolution; modest positive for tax certainty but immaterial to Q2 earnings.
4 · Ownership Stable; HRTI Trading Activity (Aug–Sep 2026)
FII holding dipped to 1.46% (Q1 FY27) from 1.58% (Q4 FY26); DII flat ~1.3%. Bulk deals show HRTI Securities active in large buy/sell blocks near ₹87–₹107 in Aug–Sep, typical of liquidity provision. No promoter pledges flagged.
5 · ESG & Corporate Governance (Sep 22, 2026)
CRISIL ESG 60 rating assigned (Sep 21), signifying 'Adequate' category. Enhances ESG profile for institutional investors; no direct earnings impact.
The Close
Morepen Labs enters Q2 FY27 earnings on Oct 27 as a momentum story—a small-cap pharma shifting from contract manufacturing to high-margin CDMO commercialization. Q1's 34% revenue growth and 394% PAT surge on ₹58 Cr CDMO dispatch set an ambitious run-rate; Q2's credibility rests on repeating the dispatch cadence (expect ~₹225 Cr additional supplies) while holding margin ≥15% and defending traditional pharma revenues. The stock has already re-rated sharply from ₹59 (Q1 pre-announcement) to ₹127.83 (current), pricing in a significant earnings re-rating. Street analyst updates remain thin—an opportunity for fresh broker consensus post-Q2.
Three things to watch on result day: (1) Q2 CDMO revenue (does it hit the ₹225 Cr incremental supply expectation?), (2) EBITDA margin—will it sustain ≥15% or compress under mix/FX/operational headwinds?, and (3) management guidance or commentary on H2 CDMO ramp and USFDA ANDA trajectory (Sitagliptin approval timelines matter for FY27–FY28 growth).
Informational and educational content only. Not investment advice.